“…Thus, VCP/p97 represents a potential prognostic biomarker and a therapeutic target. [71] Gastric cancer greater tumor size, presence of vascular and lymphatic invasion, lymph node metastasis, and shorter overall and disease free survival [72] cell survival, degradation of cellular regulators, and gastric carcinogenesis [73,74] low levels of CHOP and DR5 [75] Esophageal cancer higher frequencies of lymph node metastasis, deeper invasion, metastasis, and shorter disease free and overall survival [76] shorter overall survival [77] Breast cancer shorter overall survival [78] poor outcomes of triple-negative patients receiving chemotherapy [79,80] Hematological cancer tumor grade, stage, histological subtype, recurrence and shorter overall and disease-free survival of patients with B-cell lymphoma [104] multiple myeloma development and progression [105] poor prednisone responders in pediatric patients with acute lymphoblastic leukemia [106] exosome generation and secretion in Jurkat tumor cells [107] Melanoma advanced radiotherapy [108] immune escape [109] Glioblastoma radiosensitivity of glioblastoma cells, and survival time of xenografted mice with radiation treatment [110,111] HDAC6 levels and temozolomide resistance therapy [112] Ovarian cancer chemotherapy response in patients receiving the platinum-taxane combination [113] Testicular cancer development of different types of human testicular tumors [114] Bladder cancer shorter survival following bladder removal by cystectomy [115] Squamous cell carcinoma development of squamous cell carcinoma [116] 3.1. VCP/p97 in Gastrointestinal Cancers 3.1.1.…”